Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
Pharmacovigilance01:19

Pharmacovigilance

983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Zongertinib: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Sep 9, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K

林沃塞尔塔马布:第一次批准

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|August 29, 2025
PubMed
概括
此摘要是机器生成的。

针对BCMA和CD3的双特异性抗体Linvoseltamab已获得欧盟批准用于治疗复发性/耐药性多发性骨髓瘤. 这标志着T细胞治疗晚期血液癌症的重要里程碑.

更多相关视频

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 7, 2009

27.2K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

相关实验视频

Last Updated: Sep 9, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS

Published on: October 7, 2009

27.2K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

科学领域:

  • 癌症学
  • 免疫学
  • 药理学

背景情况:

  • 多发性骨髓瘤是一种血液恶性瘤,其特征是血细胞的不受控制的增殖.
  • 复发性/耐药性多发性骨髓瘤是一个重要的未满足的医疗需求,通常需要新的治疗策略.
  • B细胞成熟抗原 (BCMA) 是多发性骨髓瘤的有效点.

研究的目的:

  • 总结林沃塞尔塔马布的主要发展里程碑.
  • 突出欧盟对林沃塞尔塔马布的监管批准.
  • 提供linvoseltamab的作用机制及其适用情况的概述.

主要方法:

  • 林沃塞塔马布是一种双特异性抗体,被设计为结合BCMA与恶性B细胞以及CD3与T细胞.
  • 这种双重结合将T细胞重定向到参与并消除BCMA表达的瘤细胞.
  • 发展里程碑包括临床前研究,临床试验和监管提交.

主要成果:

  • 林沃塞尔塔马布于2025年4月28日在欧盟获得了首次营销许可.
  • 批准用于治疗复发性/ 耐药性多发性骨髓瘤的成年患者.
  • 患者必须先前接受至少三种治疗,包括特定类型的药物,并显示疾病进展.

结论:

  • 林沃塞尔塔马布为重度预治疗多发性骨髓瘤患者提供了一种新疗法.
  • 欧盟的批准标志着BCMA导向免疫疗法的重大进展.
  • 这一里程碑突显了双特异抗体在治疗血液恶性瘤方面的潜力.